ArticleJournal of clinical medicine2025

Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment.

Ali Atay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.